Dr. Anne Horgan holds a PhD in Synthetic Organic Chemistry from the University of Bristol. Following a postdoctoral fellowship at Yale University, she advanced into executive roles in business and project development. Currently serving as a Partner at Cambridge Innovation Capital, Dr. Horgan contributes over twenty years of investment, technology transfer, and biotechnology R&D experience to Radyus' Scientific Advisory Board. Her career began at Cancer Research Technology as a Business Development Executive, focusing on commercializing intellectual property from academic research. She then moved to Sofinnova Partners as a Senior Associate, where she managed deal sourcing, due diligence, and investment support. Subsequently, as a Partner at AdBio Partners, she concentrated on company creation and seed investments in life sciences before assuming her current position at Cambridge Innovation Capital, where she oversees deal sourcing and investments, representing CIC on portfolio company boards.

In addition to her academic achievements, Dr. Horgan's postdoctoral work at Yale involved creating novel molecules for oncology therapeutics, resulting in eight patent families and seven peer-reviewed publications. Her diverse skill set includes technical and commercial due diligence, investments, commercialization activities, and deal-making, making her a valuable asset to health innovation ventures aiming for patient benefit.